CA
CASC

CapWealth Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

CapWealth Advisors’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-244
Closed -$4K – 402
2014
Q1 		$4K Buy
+244
New +$4.01K ﹤0.01% 324

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ERSOT
Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return

CapWealth Advisors's CASC Position: Q2 2014 in Review

CapWealth Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2014, closing a stake of 244 shares — an estimated $4K sold.

CapWealth Advisors first reported a position in CASC in Q1 2014 and held it in 1 quarter. The position peaked at $4K in Q1 2014. 86 funds tracked by Wall St. Rank hold CASC as of Q2 2014.

  • CapWealth Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • CapWealth Advisors sold 244 Cascadian Therapeutics, Inc. shares in Q2 2014, an estimated $4K.
  • CapWealth Advisors first reported a position in Cascadian Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
  • CapWealth Advisors's Cascadian Therapeutics, Inc. position peaked at $4K in Q1 2014.
  • 86 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2014.

Based on CapWealth Advisors's 13F filing for Q2 2014, filed 8 Aug 2014.